Evidence map›Paper›PMID 40459946›Full record

ArticleThe Journal of clinical investigation2025

The tumor microenvironment of non-small cell lung cancer impairs immune cell function in people with HIV.

Shruti S Desai, Syim Salahuddin, Ramsey Yusuf, Kishu Ranjan, Jianlei Gu, Lais Osmani, Ya-Wei Lin, Sameet Mehta, Ronan Talmon, Insoo Kang and 4 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Roadmap for spatial transcriptomics of HIV in tissues.Current opinion in HIV and AIDS · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shruti S DesaiDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
Syim SalahuddinDepartment of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Ramsey YusufYale University School of Medicine, New Haven, Connecticut, USA.
Kishu RanjanDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
Jianlei GuDepartment of Biostatistics and.
Lais OsmaniDepartment of Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Ya-Wei LinDepartment of Electrical and Computer Engineering Technion-Israel Institute of Technology, Haifa, Israel.
Sameet MehtaYale Center for Genome Analysis, Yale University School of Medicine, New Haven, Connecticut, USA.
Ronan TalmonDepartment of Electrical and Computer Engineering Technion-Israel Institute of Technology, Haifa, Israel.
Insoo KangDepartment of Internal Medicine, Section of Rheumatology, Yale University School of Medicine, New Haven, Connecticut, USA.
Yuval KlugerDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
Hongyu ZhaoDepartment of Biostatistics and.
Kurt SchalperDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.
Brinda EmuDepartment of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA.

Funding

Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
(PQ1) Lipid Metabolism, Inflammation, and T cell Dysfunction in HIV-associated CancerR01CA206483 · NCI · YALE UNIVERSITY · PI EMU, BRINDA, KAECH, SUSAN M · 2017 to 2021
$3.2M
Quantitative and Spatially-Resolved Analysis of the Tumor Immune Contexture for Optimal Diagnosis and Treatment of Lung CancerR37CA245154 · NCI · YALE UNIVERSITY · PI SCHALPER, KURT A · 2020 to 2025
$2.6M
Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancerR01CA262377 · NCI · YALE UNIVERSITY · PI SCHALPER, KURT A · 2021 to 2025
$1.9M
Medical Student Summer Research ProgramT35HL166206 · NHLBI · UNIVERSITY OF IOWA · PI ROBERT D ROGHAIR · 2023 to 2026
$598k
NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA206483NCI NIH HHS R01 CA262377NCI NIH HHS R37 CA245154NHLBI NIH HHS T35 HL166206
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer mortality among people with HIV (PWH), with increased incidence and poor outcomes. This study explored whether the tumor microenvironment (TME) of HIV-associated non-small cell lung cancer (NSCLC) limits tumor-specific immune responses. With a matched cohort of NSCLC samples from PWH and from people without HIV (PWOH), we used imaging mass cytometry, a linear mixed-effects model, and an artificial intelligence-based (AI-based) PageRank mathematical algorithm based on spectral graph theory to demonstrate that HIV-associated tumors have differential distribution of tumor-infiltrating CD8+ and CD4+ T cells, enriched for the expression of programmed cell death 1 (PD-1) and lymphocyte-activating gene 3 (LAG3), as well as activation and proliferation markers. We also demonstrate higher expression of immunoregulatory molecules (PD-L1, PD-L2, B7-H3, B7-H4, IDO1, and VISTA) among tumor-associated macrophages. Discrimination of cells between tumors from PWH versus those from PWOH was confirmed by spectral graph theory with 84.6% accuracy. Furthermore, we noted differences in spatial orientation of immune cells within the TME of PWH compared with PWOH. Additionally, cells from PWH, compared with those from PWOH, exhibited decreased tumor killing when exposed to HLA-matched NSCLC cell lines. In conclusion, our study demonstrates that the HIV-associated TME sustained a unique immune landscape, showing evidence of immune cells with enhanced immunoregulatory phenotypes and impaired antitumor responses, with implications for responses to immune checkpoint blocker therapies.

Indexed as

Carcinoma, Non-Small-Cell LungCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHIV InfectionsLung NeoplasmsLymphocytes, Tumor-InfiltratingNeoplasm ProteinsTumor MicroenvironmentFemaleHumansMaleMiddle AgedNeoplasm ProteinsAIDS/HIVImmunologyLung cancerOncology

Identifiers

PMID40459946
PMCPMC12259253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.